Use of an extract from a culture of thermophilic strain Staphylococcus aureusin the complex therapy of a patient with atopic dermatitis: a clinical case
- Authors: Smolnikov E.V.1,2, Sklyarova V.O.2, Shtyrbul T.I.3, Litovkina A.O.1,2, Shtyrbul O.V.1, Elisyutina O.G.1,2, Fedenko E.S.2
-
Affiliations:
- National Research Center — Institute of Immunology Federal Medical-Biological Agency of Russia
- Peoples’ Friendship University of Russia
- The First Sechenov Moscow State Medical University (Sechenov University)
- Issue: Vol 22, No 1 (2025)
- Pages: 86-94
- Section: Case reports
- URL: https://journals.rcsi.science/raj/article/view/312966
- DOI: https://doi.org/10.36691/RJA17006
- ID: 312966
Cite item
Open Access
Access granted
Subscription Access
Abstract
Atopic dermatitis refers to type 2 inflammatory disease. It is associated with genetic predisposition to allergies, immune dysregulation, skin barrier dysfunction and characterized by chronic relapsing course. Activation of T2 inflammation in atopic dermatitis is a complex interaction between innate and adaptive immune mechanisms, epidermal cells, nervous system, and microbial factors, leads to the development of local and systemic inflammation, characterized by activation and proliferation of type 2 T-helper cells, group 2 innate lymphoid cells, and the involvement of pro-inflammatory type 2 cytokines. Understanding these processes opens opportunities for targeted biological therapy and selective immunosuppressive therapy aimed at blocking key cytokines of T2 inflammation. Agents with non-specific action affecting immune dysregulation in allergic diseases are also being introduced into clinical practice. They are presented by specific natural or recombinant regulatory peptides and proteins. One of such drugs is a pharmaceutical product with an extract from thermophilic strain Staphylococcus aureus culture as an active substance.
The article presents a clinical case of an adult patient with severe atopic dermatitis complicated by bacterial infection with positive response to use a drug, based on an extract from thermophilic strain Staphylococcus aureus culture.
Full Text
##article.viewOnOriginalSite##About the authors
Evgeniy V. Smolnikov
National Research Center — Institute of Immunology Federal Medical-Biological Agency of Russia; Peoples’ Friendship University of Russia
Author for correspondence.
Email: qweril2010@yandex.ru
ORCID iD: 0000-0003-1302-4178
SPIN-code: 4874-8100
MD, Research Associate
Russian Federation, Moscow; MoscowVictoria O. Sklyarova
Peoples’ Friendship University of Russia
Email: viktoriafedotova3@gmail.com
ORCID iD: 0009-0002-9035-1674
Russian Federation, Moscow
Taisiya I. Shtyrbul
The First Sechenov Moscow State Medical University (Sechenov University)
Email: taisakisa@yandex.ru
ORCID iD: 0009-0008-1292-4223
Russian Federation, Moscow
Alla O. Litovkina
National Research Center — Institute of Immunology Federal Medical-Biological Agency of Russia; Peoples’ Friendship University of Russia
Email: dr.litovkina@gmail.com
ORCID iD: 0000-0002-5021-9276
SPIN-code: 2337-7930
MD, Research Associate
Russian Federation, Moscow; MoscowOlga V. Shtyrbul
National Research Center — Institute of Immunology Federal Medical-Biological Agency of Russia
Email: ovs-495@yandex.ru
ORCID iD: 0000-0001-8254-9715
SPIN-code: 4146-1788
Russian Federation, Moscow
Olga G. Elisyutina
National Research Center — Institute of Immunology Federal Medical-Biological Agency of Russia; Peoples’ Friendship University of Russia
Email: el-olga@yandex.ru
ORCID iD: 0000-0002-4609-2591
SPIN-code: 9567-1894
MD, Dr. Sci. (Medicine)
Russian Federation, Moscow; MoscowElena S. Fedenko
Peoples’ Friendship University of Russia
Email: efedks@gmail.com
ORCID iD: 0000-0003-3358-5087
SPIN-code: 5012-7242
MD, Dr. Sci. (Medicine)
Russian Federation, MoscowReferences
- Kubanov AA, Namazova-Baranova LS, Khaitov RM, et al. Atopic dermatitis. Russian Journal of Allergy. 2021;18(3):44–92. (In Russ.). doi: 10.36691/RJA1474
- Laughter MR, Maymone MBC, Mashayekhi S, et al. The global burden of atopic dermatitis: lessons from the Global Burden of Disease Study 1990–2017. Br J Dermatol. 2021;184(2):304–309. doi: 10.1111/bjd.19580
- Schuler CF, Billi AC, Maverakis E, et al. Novel insights into atopic dermatitis. J Allergy Clin Immunol. 2023;151(5):1145–1154. doi: 10.1016/j.jaci.2022.10.023
- Weidinger S, Beck LA, Bieber T, et al. Atopic dermatitis. Nat Rev Dis Primers. 2018;4(1):1. doi: 10.1038/s41572-018-0001-z
- Moosbrugger-Martinz V, Leprince C, Méchin MC, et al. Revisiting the roles of filaggrin in atopic dermatitis. Iint J Mol Sci. 2022;23(10):5318. doi: 10.3390/ijms23105318
- Furue M. Regulation of filaggrin, loricrin, and involucrin by IL-4, IL-13, IL-17A, IL-22, AHR, and NRF2: pathogenic implications in atopic dermatitis. Iint J Mol Sci. 2020;21(15):5382. doi: 10.3390/ijms21155382
- Van Smeden J, Bouwstra JA. Stratum corneum lipids: their role for the skin barrier function in healthy subjects and atopic dermatitis patients. Curr Probl Dermatol. 2016;49:8–26. doi: 10.1159/000441540
- Suwanchote S, Waitayangkoon P, Chancheewa B, et al. Role of antimicrobial peptides in atopic dermatitis. Int J Dermatology. 2022;61(5):532–540. doi: 10.1111/ijd.15814
- Werfel T, Allam JP, Biedermann T, et al. Cellular and molecular immunologic mechanisms in patients with atopic dermatitis. J Allergy Clin Immunol. 2016;138(2):336–349. doi: 10.1016/j.jaci.2016.06.010
- Edslev S, Agner T, Andersen P. Skin microbiome in atopic dermatitis. Acta Derm Venereol. 2020;100(12):adv00164. doi: 10.2340/00015555-3514
- Thammahong A, Kiatsurayanon C, Edwards SW, et al. The clinical significance of fungi in atopic dermatitis. Int J Dermatol. 2020;59(8):926–935. doi: 10.1111/ijd.14941
- Elisyutina OG, Fedenko ES, Smolnikov EV, et al. Diagnostic and prognostic value of biomarkers in atopic dermatitis for assessing its endotypes, phenotypes, and treatment efficacy. Russian Journal of Allergy. 2023;20(4):521–542. (In Russ.). doi: 10.36691/RJA16905
- Joshi AA, Vocanson M, Nicolas JF, et al. Microbial derived antimicrobial peptides as potential therapeutics in atopic dermatitis. Front Immunol. 2023;14:1125635. doi: 10.3389/fimmu.2023.1125635
- Terekhova EP, Terekhov DV, Sebekina OV. Application of the drug Ruzam in the treatment and prevention of allergic diseases. Practical Allergology. 2021;(1):54–65. (In Russ.). doi: 10.46393/2712-9667_2021_1_54-64
- Ministry of health of Russia. Ruzam®. Instructions for the use of the medicinal product for medical application [electronic resource]. Available from: https://cdn.pharm-portal.ru/69jxs7cjr4n4gdc2acy5y4x8/instructions/ЛС-000791/InstrImg_2021_11_10_1417450/2d27b7ff-8198-4a22-a4aa-8f16f3213402.pdf Accessed: 22.01.2025. (In Russ.).
- Thyssen JP, Halling AS, Schmid-Grendelmeier P, et al. Comorbidities of atopic dermatitis — what does the evidence say? J Allergy Clin Immunol. 2023;151(5):1155–1162. doi: 10.1016/j.jaci.2022.12.002
- Totté JE, van der Feltz WT, Hennekam M, et al. Prevalence and odds of staphylococcus aureus carriage in atopic dermatitis: a systematic review and meta-analysis. Br J Dermatol. 2016;175(4):687–695. doi: 10.1111/bjd.14566
- Kolesnikova NV, Kozlov IG, Guryanova SV, et. al. Сlinical and immunological efficiency of muramyl dipeptide in the treatment of atopic diseases. Medical Immunology (Russia). 2016;18(1):15–20. (In Russ.). doi: 10.15789/1563-0625-2016-1-15-20
- Gajchieva ZN. Evaluation of efficacy, safety and long-term results of action of polypeptide medicine “Rusam” in complex therapy of patients with bronchial asthma and atopic dermatitis. Dis. … candidate of medical sciences. Moscow, 2005. Available from: https://medical-diss.com/docreader/277452/d?#?page=1. (In Russ.).
Supplementary files
